Detail akcie Panacos Pharma online

Business Summary: Panacos Pharmaceuticals, Inc. (Panacos) is a development-stage biotechnology company that seeks to develop next generation anti-infective products through the discovery and development of small-molecule oral drugs designed to treat human immunodeficiency virus (HIV) and other human viral diseases. The Company's lead product candidate, bevirimat, is an oral HIV drug candidate in Phase II clinical testing. Panacos has dosed over 485 patients and subjects with bevirimat and have seen a good safety and tolerability profile with no indication of a relationship between adverse events and drug levels. The Company has exclusive rights from University of North Carolina at Chapel Hill (UNC) to the United States patent claiming the chemical entity bevirimat. Panacos has an exclusive worldwide license with UNC for all indications.
Financial Summary: BRIEF: For the 39 weeks ended 30 September 2008, Panacos Pharmaceuticals, Inc. revenues decreased 51% to $77K. Net loss decreased 6% to $26.4M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Lower net loss reflects Research and Development decrease of 9% to $17.1M (expense), In Process R&D decrease from $1.2M (expense) to $0K, Impairment and contract related charges decrease from $54K